Search

Displaying results 3591 - 3600 of 5263 in total
  1. Drug

    Motuporin

    go.drugbank.com/drugs/DB04738
    Experimental

    Motuporin is a toxin isolated from the marine sponge Thenonella swinhoie grey.

  2. Drug

    Benzoctamine

    go.drugbank.com/drugs/DB09021
    Experimental

    It can be used as a sedative which does not depress the respiratory system, but rather stimulates it.

    Synonyms: N-Methyl-9,10-ethanoanthracene-9(10H)-methanamine
  3. Drug

    Nafarelin

    go.drugbank.com/drugs/DB00666
    ApprovedInvestigational

    Nafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central precocious puberty and endometriosis.

  4. Drug

    Incadronic acid

    go.drugbank.com/drugs/DB06255
    Experimental

    Incadronate, or YM-175, is a nitrogen containing bisphosphonate. Along with being investigated to treat hypercalcemia of malignancy, it has also been investigated in the treatment of myeloma, leukemia, and other cancers. Incadronic acid ...

  5. Drug

    RAV12

    go.drugbank.com/drugs/DB05140
    Investigational

    RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.

  6. Drug

    Anifrolumab

    go.drugbank.com/drugs/DB11976
    ApprovedInvestigational

    Three monoclonal antibodies (anifrolumab, [rontalizumab], and [sifalimumab]) that target the type 1 interferon pathway entered clinical trials as potential treatments for systemic lupus erythematosus, but

  7. Drug

    Casimiroin

    go.drugbank.com/drugs/DB08744
    Experimental

    Casimiroin is a quinone reductase 2 inhibitor isolated from _Casimiroa edulis_.

  8. Drug

    Kitasamycin

    go.drugbank.com/drugs/DB09309
    Experimental

    Kitasamycin is a macrolide antibiotic derived from <em>Streptomyces kitasatoensis</em>.

  9. Drug

    Posizolid

    go.drugbank.com/drugs/DB04850
    Investigational

    no results were reported). … In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though

  10. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. … DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.